3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Angiogenesis, Pathologic in 13 studies
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HIF-1 activity in tumors depends on availability of the HIF-1α subunit, the levels of which increase under hypoxic conditions and through activation of oncogenes and/or inactivation of tumor suppressor genes." | 2.48 | Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. ( Choi, HK; Lee, K; Xia, Y, 2012) |
| "Hep3B hepatoma, NCI-H87 stomach carcinoma, Caki-1 renal carcinoma, SiHa cervical carcinoma, and SK-N-MC neuroblastoma cells were grown as xenografts in immunodeficient mice (69 mice total)." | 1.32 | YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. ( Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, Y | 1 |
| Choi, HK | 1 |
| Lee, K | 1 |
| Chang, LH | 1 |
| Pan, SL | 3 |
| Lai, CY | 1 |
| Tsai, AC | 1 |
| Teng, CM | 3 |
| Wen, Y | 1 |
| Li, J | 1 |
| Koo, J | 1 |
| Shin, SS | 1 |
| Lin, Y | 1 |
| Jeong, BS | 1 |
| Mehnert, JM | 1 |
| Chen, S | 1 |
| Cohen-Sola, KA | 1 |
| Goydos, JS | 1 |
| Subhani, S | 1 |
| Vavilala, DT | 1 |
| Mukherji, M | 1 |
| DeNiro, M | 1 |
| Al-Halafi, A | 1 |
| Al-Mohanna, FH | 1 |
| Alsmadi, O | 1 |
| Al-Mohanna, FA | 1 |
| Liu, L | 1 |
| Yu, Q | 1 |
| Lin, J | 1 |
| Lai, X | 1 |
| Cao, W | 1 |
| Du, K | 1 |
| Wang, Y | 1 |
| Wu, K | 1 |
| Hu, Y | 1 |
| Zhang, L | 1 |
| Xiao, H | 1 |
| Duan, Y | 1 |
| Huang, H | 1 |
| Kong, J | 2 |
| Pan, B | 1 |
| Ke, S | 1 |
| Dong, S | 1 |
| Li, X | 1 |
| Zhou, A | 1 |
| Zheng, L | 1 |
| Sun, WB | 1 |
| Dal Monte, M | 1 |
| Landi, D | 1 |
| Martini, D | 1 |
| Bagnoli, P | 1 |
| Pili, R | 1 |
| Donehower, RC | 1 |
| Yeo, EJ | 1 |
| Chun, YS | 1 |
| Cho, YS | 1 |
| Kim, J | 1 |
| Lee, JC | 1 |
| Kim, MS | 1 |
| Park, JW | 1 |
| Guh, JH | 2 |
| Peng, CY | 2 |
| Wang, SW | 1 |
| Chang, YL | 2 |
| Cheng, FC | 1 |
| Chang, JH | 1 |
| Kuo, SC | 2 |
| Lee, FY | 2 |
| Garber, K | 1 |
| Liu, YN | 1 |
| Huang, DM | 1 |
| Lin, CH | 1 |
| Pai, HC | 1 |
2 reviews available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Hypo | 2012 |
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Anthracyclines; Biphenyl Compounds; | 2016 |
11 other studies available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis.
Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Down-Regulation; Flavonoids; Humans; | 2013 |
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia-Ind | 2014 |
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Indazoles; Mice; Mice, Inbred C57BL; Neovasculari | 2010 |
Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood.
Topics: Animals; Blood Cells; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Movement; Cells, Cu | 2011 |
Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablatio | 2012 |
Antiangiogenic role of miR-361 in human umbilical vein endothelial cells: functional interaction with the peptide somatostatin.
Topics: Algorithms; Angiogenesis Inhibitors; Blotting, Western; Cell Hypoxia; Cell Proliferation; Down-Regul | 2013 |
Is HIF-1 alpha a valid therapeutic target?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Basic Helix- | 2003 |
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell | 2003 |
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Blotting, Western; Cell Movement; Cell Prolif | 2005 |
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Inve | 2005 |
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9.
Topics: Angiogenesis Inhibitors; Animals; Carotid Arteries; Catheterization; Cyclic GMP; Enzyme-Linked Immun | 2006 |